Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,828 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors.
Seki Y, Yamamoto N, Tamura Y, Goto Y, Shibata T, Tanioka M, Asahina H, Nokihara H, Yamada Y, Shimamoto T, Noguchi K, Tamura T. Seki Y, et al. Among authors: tamura t, tamura y. Cancer Chemother Pharmacol. 2012 Apr;69(4):1099-105. doi: 10.1007/s00280-011-1788-4. Epub 2011 Dec 6. Cancer Chemother Pharmacol. 2012. PMID: 22143378 Free PMC article. Clinical Trial.
Innovator and generic cisplatin formulations: comparison of renal toxicity.
Sekine I, Kubota K, Tamura Y, Asahina H, Yamada K, Horinouchi H, Nokihara H, Yamamoto N, Tamura T. Sekine I, et al. Among authors: tamura t, tamura y. Cancer Sci. 2011 Jan;102(1):162-5. doi: 10.1111/j.1349-7006.2010.01764.x. Epub 2010 Nov 5. Cancer Sci. 2011. PMID: 21054679 Free PMC article.
An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.
Asahina H, Tamura Y, Nokihara H, Yamamoto N, Seki Y, Shibata T, Goto Y, Tanioka M, Yamada Y, Coates A, Chiu YL, Li X, Pradhan R, Ansell PJ, McKeegan EM, McKee MD, Carlson DM, Tamura T. Asahina H, et al. Among authors: tamura t, tamura y. Cancer Chemother Pharmacol. 2012 Jun;69(6):1477-86. doi: 10.1007/s00280-012-1846-6. Epub 2012 Mar 2. Cancer Chemother Pharmacol. 2012. PMID: 22382879 Free PMC article. Clinical Trial.
Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors.
Honda K, Yamamoto N, Nokihara H, Tamura Y, Asahina H, Yamada Y, Suzuki S, Yamazaki N, Ogita Y, Tamura T. Honda K, et al. Among authors: tamura t, tamura y. Cancer Chemother Pharmacol. 2013 Sep;72(3):577-84. doi: 10.1007/s00280-013-2228-4. Epub 2013 Jul 17. Cancer Chemother Pharmacol. 2013. PMID: 23860959 Clinical Trial.
Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.
Nakamichi S, Nokihara H, Yamamoto N, Yamada Y, Fujiwara Y, Tamura Y, Wakui H, Honda K, Mizugaki H, Kitazono S, Tanabe Y, Asahina H, Yamazaki N, Suzuki S, Matsuoka M, Ogita Y, Tamura T. Nakamichi S, et al. Among authors: tamura t, tamura y. Invest New Drugs. 2015 Jun;33(3):641-51. doi: 10.1007/s10637-015-0229-3. Epub 2015 Mar 27. Invest New Drugs. 2015. PMID: 25809858 Clinical Trial.
A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors.
Nakamichi S, Nokihara H, Yamamoto N, Yamada Y, Honda K, Tamura Y, Wakui H, Sasaki T, Yusa W, Fujino K, Tamura T. Nakamichi S, et al. Among authors: tamura t, tamura y. Cancer Chemother Pharmacol. 2015 Dec;76(6):1153-61. doi: 10.1007/s00280-015-2899-0. Epub 2015 Nov 3. Cancer Chemother Pharmacol. 2015. PMID: 26530955 Free PMC article. Clinical Trial.
2,828 results